Literature DB >> 18081008

Calibration of the Andersen cascade impactor for the characterization of nasal products.

Robert J Garmise1, Anthony J Hickey.   

Abstract

Current cascade impactor protocols do not completely rule out nasal preparations entering the lower respiratory tract. A modified cascade impactor (MCI) was developed to characterize the particle size fraction capable of deposition in the lower respiratory tract. This is an important measure of the potential for delivery to a site which is not the route of administration, and which could lead to potential toxicity. Monodisperse aerosols were utilized to calibrate the Stage -2 and Stage -0 of an Andersen Mk II nonviable cascade impactor at 15 L per minute flow rate. While these sampling conditions are beyond the normal working range of impactor theory in practice the instrument was shown to discriminate the designated particle sizes sampled. This novel setup extended the upper limit of the range of particle sizes that the cascade impactor can characterize from 8.7 to 16.5 microm.

Entities:  

Mesh:

Year:  2008        PMID: 18081008     DOI: 10.1002/jps.21267

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor.

Authors:  William H Doub; Wallace P Adams; Anna M Wokovich; John C Black; Meiyu Shen; Lucinda F Buhse
Journal:  Pharm Res       Date:  2012-07-03       Impact factor: 4.200

2.  Deposition Pattern of Polydisperse Dry Powders in Andersen Cascade Impactor - Aerodynamic Assessment for Inhalation Experimentally and In Silico.

Authors:  Janwit Dechraksa; Tan Suwandecha; Teerapol Srichana
Journal:  Turk J Pharm Sci       Date:  2020-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.